MedTrace Logo

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

NCT06204679 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-09-19

No results posted yet for this study

Summary

This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions

A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)

DRUG

Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions

A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)

DRUG

Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions

Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations

Sponsors & Collaborators

  • Atea Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-14
Primary Completion
2024-08-25
Completion
2024-08-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06204679 on ClinicalTrials.gov